Comparative effectiveness of canagliflozin, SGLT2 inhibitors and non-SGLT2 inhibitors on the risk of hospitalization for heart failure and amputation in patients with type 2 diabetes mellitus: A real-world meta-analysis of 4 observational databases (OBSERVE-4D) - PubMed (original) (raw)

Meta-Analysis

. 2018 Nov;20(11):2585-2597.

doi: 10.1111/dom.13424. Epub 2018 Jun 25.

Affiliations

Meta-Analysis

Comparative effectiveness of canagliflozin, SGLT2 inhibitors and non-SGLT2 inhibitors on the risk of hospitalization for heart failure and amputation in patients with type 2 diabetes mellitus: A real-world meta-analysis of 4 observational databases (OBSERVE-4D)

Patrick B Ryan et al. Diabetes Obes Metab. 2018 Nov.

Abstract

Aims: Sodium glucose co-transporter 2 inhibitors (SGLT2i) are indicated for treatment of type 2 diabetes mellitus (T2DM); some SGLT2i have reported cardiovascular benefit, and some have reported risk of below-knee lower extremity (BKLE) amputation. This study examined the real-world comparative effectiveness within the SGLT2i class and compared with non-SGLT2i antihyperglycaemic agents.

Materials and methods: Data from 4 large US administrative claims databases were used to characterize risk and provide population-level estimates of canagliflozin's effects on hospitalization for heart failure (HHF) and BKLE amputation vs other SGLT2i and non-SGLT2i in T2DM patients. Comparative analyses using a propensity score-adjusted new-user cohort design examined relative hazards of outcomes across all new users and a subpopulation with established cardiovascular disease.

Results: Across the 4 databases (142 800 new users of canagliflozin, 110 897 new users of other SGLT2i, 460 885 new users of non-SGLT2i), the meta-analytic hazard ratio estimate for HHF with canagliflozin vs non-SGLT2i was 0.39 (95% CI, 0.26-0.60) in the on-treatment analysis. The estimate for BKLE amputation with canagliflozin vs non-SGLT2i was 0.75 (95% CI, 0.40-1.41) in the on-treatment analysis and 1.01 (95% CI, 0.93-1.10) in the intent-to-treat analysis. Effects in the subpopulation with established cardiovascular disease were similar for both outcomes. No consistent differences were observed between canagliflozin and other SGLT2i.

Conclusions: In this large comprehensive analysis, canagliflozin and other SGLT2i demonstrated HHF benefits consistent with clinical trial data, but showed no increased risk of BKLE amputation vs non-SGLT2i. HHF and BKLE amputation results were similar in the subpopulation with established cardiovascular disease. This study helps further characterize the potential benefits and harms of SGLT2i in routine clinical practice to complement evidence from clinical trials and prior observational studies.

Keywords: SGLT2 inhibitor; type 2 diabetes.

© 2018 The Authors. Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd.

PubMed Disclaimer

Conflict of interest statement

Canagliflozin was developed by Janssen Research & Development, LLC, in collaboration with Mitsubishi Tanabe Pharma Corporation.

P. B. R., M. J. S., F. D., Z. Y., P. E. S. and N. R. are full‐time employees of Janssen Research & Development, LLC. J. A. B. is a full‐time employee of Johnson & Johnson, LLC.

J. B. B. has received contracted consulting fees, paid to his institution, and travel support from Adocia, AstraZeneca, Dexcom, Elcelyx Therapeutics, Eli Lilly, Intarcia Therapeutics, Lexicon, Metavention, NovaTarg, Novo Nordisk, Sanofi, Senseonics and vTv Therapeutics; has received grant support from AstraZeneca, Boehringer Ingelheim, Johnson & Johnson, Lexicon, Novo Nordisk, Sanofi, Theracos and vTv Therapeutics; holds stock options in Mellitus Health and PhaseBio; has served on the board of the AstraZeneca HealthCare Foundation; and is supported by a grant from the National Institutes of Health (UL1TR002489).

Figures

Figure 1

Figure 1

Kaplan–Meier plots for on‐treatment comparisons of canagliflozin vs all non‐SGLT2i for HHF and BKLE amputation. Abbreviations: CCAE, Truven MarketScan Commercial Claims and Encounters; MDCD, Truven MarketScan Multi‐state Medicaid; MDCR, Truven MarketScan Medicare Supplemental Beneficiaries; ITT, intent‐to‐treat; BKLE, below‐knee lower extremity; HHF, hospitalization for heart failure

Figure 2

Figure 2

Forest plot of effect estimates for risk of amputation from all sensitivity analyses across databases and time‐at‐risk periods. Abbreviations: CCAE, Truven MarketScan Commercial Claims and Encounters; MDCD, Truven MarketScan Multi‐state Medicaid; MDCR, Truven MarketScan Medicare Supplemental Beneficiaries; ITT, intent‐to‐treat; SGLT2i, sodium glucose co‐transporter 2 inhibitors; HKSJ, Hartung‐Knapp‐Sidik‐Jonkman; DL, DerSimonian‐Laird

Comment in

Similar articles

Cited by

References

    1. Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377:644‐657. - PubMed
    1. Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Matthews DR. The Integrated Results of the CANVAS Program. Presented at: The 77th Scientific Sessions of the American Diabetes Association (ADA); June 12, 2017; San Diego, CA. https://professional.diabetes.org/sites/professional.diabetes.org/files/.... Accessed December 5, 2017.
    1. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117‐2128. - PubMed
    1. Inzucchi SE, Iliev H, Pfarr E, Zinman B. Empagliflozin and assessment of lower‐limb amputations in the EMPA‐REG OUTCOME trial. Diabetes Care. 2018;41:e4‐e5. - PubMed
    1. Kosiborod M, Cavender MA, Fu AZ, et al. Lower risk of heart failure and death in patients initiated on SGLT‐2 inhibitors versus other glucose‐lowering drugs: the CVD‐REAL Study. Circulation. 2017;136:249‐259. - PMC - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources